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abstract: Guidelines on karyotyping infertile men before ICSI treatment are not consistent. Most guidelines recommend chromosomal
screening in azoospermic and severe oligozoospermic men, because they are assumed to have the highest risk of abnormalities. We per-
formed a retrospective cohort study in azoospermic men and men eligible for ICSI. We determined the prevalence of chromosomal abnorm-
alities in relation to sperm concentration and compared our data to studies in the literature. A high prevalence of chromosomal abnormalities
in azoospermic men was found, but no difference in the prevalence of abnormalities was seen between different sperm concentration
categories in non-azoospermic men. This raises the question of who should be screened for chromosomal abnormalities before ICSI treat-
ment. Considering the costs and beneﬁts, we would propose limiting screening to infertile couples with non-obstructive azoospermia.
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Introduction
It is generally assumed that the prevalence of chromosomal abnorm-
alities, numerical as well as structural aberrations, is increased in infer-
tile men (ﬁrst reported by Chandley et al., 1975), and that the risk of
abnormalities is inversely related to sperm concentration (Chandley,
1979; De Braekeleer and Dao, 1991; Yoshida et al., 1997; Tuerlings
et al., 1998; Peschka et al., 1999; Vincent et al., 2002). No correlation
between sperm motility or morphology and prevalence of chromoso-
mal abnormalities has been found (Matsuda et al., 1991; Pandiyan and
Jequier, 1996; Van Assche et al., 1996; Haidl et al., 2000; Gekas et al.,
2001; Bonduelle et al., 2002).
The reported prevalence of chromosomal abnormalities in infertile
men varies among studies from 3 to 19% (summarized in Martin,
2008). This might be due to differences in the population studied,
since in some studies all men attending fertility clinics were karyo-
typed, while in others only azoospermic or oligozoospermic men
were tested. Furthermore, the deﬁnition of oligozoospermia varies
widely, as some studies only include males with sperm counts ,10
million/ml, while others report on men with sperm counts ,30
million/ml.
After the introduction of ICSI as a means to enable men with poor
sperm quality to father their own children, there have been concerns
of facilitating transmission of genetic abnormalities to their offspring.
Therefore, guidelines have been issued about karyotyping men
before starting ICSI. However, guidelines and the practice of chromo-
somal testing are not consistent and vary among countries.
The American Society of Reproductive Medicine (ASRM)
recommends that karyotyping should be offered to men who have
non-obstructive azoospermia or severe oligozoospermia (deﬁned as
,5–10 million sperm/ml) prior to performing ICSI with their
sperm (AUA and ASRM, 2006). In the UK, the National Institute
for Clinical Excellence (NICE) guideline states that men should be kar-
yotyped if the indication for ICSI is a ‘severe deﬁcit of semen quality’
or non-obstructive azoospermia. The deﬁnition of severe deﬁcit of
semen quality, however, is not given in the guideline (NICE, 2004).
Karyotyping men with a total motile sperm count ,1 million is rec-
ommended by the Dutch Society of Obstetrics and Gynaecology
and, irrespective of sperm quality, karyotyping is considered a prere-
quisite for ICSI treatment (NVOG, 1999).
Because of inconsistent guidelines and ill-deﬁned sperm limits for
screening infertile men for chromosomal abnormalities, we performed
a retrospective cohort study in men visiting our fertility clinic and
looked for comparable studies in the literature. We determined the
prevalence of chromosomal abnormalities in relation to sperm
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All male partners of couples applying for ICSI, irrespective of their sperm
quality and all azoospermic men visiting the fertility clinic of the University
Medical Centre Groningen between November 1994 and October 2007
were offered a chromosomal analysis in accordance with the prevailing
guideline of the Dutch Society of Obstetrics and Gynaecology. Data
were collected retrospectively by chart review, and only men whose
results of chromosomal analysis and at least one sperm analysis were avail-
able, participated in the study. In the Netherlands, no ethical board
approval is required for retrospective chart review and collection of anon-
ymized data.
Men were deﬁned as having a chromosomal abnormality in case of a
numerical or structural gonosomal aberration, a translocation or inversion.
Polymorphisms like the pericentric inversion in chromosome nine and het-
erochromatic variants were considered normal (Gardner and Sutherland,
2004). To allow comparison of prevalences of chromosomal abnormalities
according to sperm quality, sperm concentration was categorized. Because
no uniform categories of sperm concentration exist, we used cut-off levels
frequently mentioned in the literature (azoospermia, 1, 5, 10 and 20
million/ml).
Literature
We searched the literature for studies reporting on prevalence of chromo-
somal abnormalities in male partners of couples eligible for ICSI, in which
sperm concentration was given in relation to the abnormalities found. We
only included studies presenting data in accordance with the sperm con-
centration categories we used in our cohort study. We excluded studies
in which the karyotypes found were not explicitly given, and studies in
which less than 20 metaphases were analysed. Twenty metaphases is com-
monly considered the minimum criterion to exclude clinically relevant
mosaics (Wiktor et al., 2009). Studies presenting known polymorphisms
as chromosomal abnormalities were also excluded. Furthermore, studies
reporting on chromosomal analysis of spermatozoa were not taken into
account.
Results
In our cohort study, 1222 men were included, of whom 38 (3.1%) had
a chromosomal abnormality. In the literature eight studies were ident-
iﬁed that met our inclusion criteria. These studies represent a popu-
lation of 3807 men, and in 295 cases (7.7%) a chromosomal
abnormality was reported. The prevalences of chromosomal abnorm-
alities according to the different categories of sperm concentration for
the studies reported in the literature and for our cohort are given in
Table I.
The conﬁdence intervals (CIs) show that our results are compar-
able with the results reported in the literature in all sperm concen-
tration categories. When all data were considered, no signiﬁcant
differences were found between the percentages of chromosomal
abnormalities in the different sperm concentration categories,
except for azoospermia. Signiﬁcantly more chromosomal abnormal-
ities were found in azoospermic men (15.4%) than in non-
azoospermic men (2.5%).
Discussion
It is assumed that males with poor sperm concentration carry a high
risk of chromosomal abnormalities, as is reﬂected by the recommen-
dations in the various guidelines on karyotyping infertile men. In our
cohort and in the literature, however, the prevalence of chromosomal
abnormalities did not differ signiﬁcantly between the different sperm
concentration categories, apart from a signiﬁcantly higher prevalence
in the group of azoospermic men.
In men with normal sperm concentration [i.e. .20 million/ml
(WHO, 1999)], prevalences of chromosomal abnormalities of 2.3%
in our cohort and 3.1% in the literature were found. This questions
the assumption that sperm concentration is the single best parameter
for identifying a population at risk for chromosomal abnormalities as
indicted by the recommendations in the ASRM and NICE guidelines.
All men included in our cohort and in the literature reviewed were eli-
gible for ICSI. Oligozoospermia was not the only indication for ICSI, as
ICSI was offered to couples in case of normal sperm concentration but
poor sperm motility or morphology, or in case of fertilization failure in
a previous IVF treatment in spite of apparently normal sperm quality.
An association between sperm motility or sperm morphology and
chromosomal abnormalities in men has not been reported in the lit-
erature (Matsuda et al., 1991; Pandiyan and Jequier, 1996; Van
Assche et al., 1996; Haidl et al., 2000; Gekas et al., 2001; Bonduelle
et al., 2002). However, not all these studies exclusively investigated
men eligible for ICSI—most focused on a broader population of infer-
tile men or even men with normozoospermia. It may be suggested
that when ICSI is indicated despite normal sperm concentration,
men carry a higher risk of having a chromosomal abnormality. Further-
more, fertilization failure in IVF may reﬂect poor oocyte quality, but it
may also be considered as an indicator of poor fertilizing ability of the
sperm because of an aberrant chromosomal make-up and a chromo-
somal abnormality in the male.
In our cohort and in the literature, the highest prevalence of chro-
mosomal abnormalities was found in men with azoospermia. In our
retrospective cohort study, it was not possible to distinguish
between males with obstructive azoospermia and men with non-
obstructive azoospermia. The study of Vincent et al. was the only
study meeting the inclusion criteria of our review in which a distinction
was made between non-obstructive and obstructive azoospermia.
They reported a prevalence of chromosomal abnormalities of 16.7
and 2.1%, respectively (Vincent et al., 2002). This indicates that non-
obstructive azoospermic males carry a higher risk of chromosomal
abnormalities.
In all non-azoospermic males tested in our cohort and in the litera-
ture, the percentage of abnormal karyotypes was 2.5% (95% CI 2.0–
3.0%). Very few studies on karyotyping have been performed in large,
non-selected groups, and therefore reference data are rare. In unse-
lected newborns the prevalence of chromosomal abnormalities was
0.8% (CI 0.8–0.9%) (Nielsen and Wohlert, 1991), and in normozoo-
spermic sperm donors of proven fertility an abnormal karyotype was
noted in 0.4% (CI 0.3–0.5%) of cases (Ravel et al., 2006).
There are several reports on the prevalence of abnormal karyo-
types in infertile populations. Chromosomal abnormalities were
found in 1.0% (CI 0.5–1.4%) of normozoospermic male partners of
infertile couples visiting fertility clinics (Clementini et al., 2005). In
female partners of infertile couples, irrespective of the cause of
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Azoospermiaa 86 15 17.4 9.4–25.5 Akgul et al. (2009)
50 8 16.0 5.8–26.2 Martinez-Garza et al.
(2008)
108 21 19.4 11.9–26.9 Mohammed et al.
(2007)
77 9 11.7 4.5–18.9 Cruger et al. (2003)
49 3 6.1 0–12.8 Bor et al. (2002)
358 67 18.7 14.7–22.8 Gekas et al. (2001)
792 111 14.0 11.6–16.4 Vincent et al. (2002)
Total literature 1520 234 15.4 13.6–17.2
79 12 15.2 7.1–23.3 Present study
All data 1599 246 15.4 13.6–17.2
.0–≤1 47 1 2.1 0–6.2 Cruger et al. (2003)
149 3 2.0 0–4.3 Bor et al. (2002)
24 2 8.3 0–19.3 van der Ven et al.
(1997)
Total literature 220 6 2.7 0.6–4.9
319 10 3.1 1.2–5.0 Present study
All data 539 16 3.0 1.5–4.4
.1–≤5 92 3 3.3 0–7.0 Cruger et al. (2003)
94 3 3.1 0–6.6 Bor et al. (2002)
39 1 2.6 0–7.6 van der Ven et al.
(1997)
Total literature 225 7 3.1 0.8–5.4
250 3 1.2 0–2.6 Present study
All data 475 10 2.1 0.8–3.4
.5–≤10 628 27 4.3 2.7–5.9 Vincent et al. (2002)
40 1 2.5 0–7.3 van der Ven et al.
(1997)
Total literature 668 28 4.2 2.7–5.7
211 3 1.4 0–3.0 Present study
All data 879 31 3.5 2.3–4.7
.10–≤20 583 3 0.5 0–1.1 Vincent et al. (2002)
34 0 0 van der Ven et al.
(1997)
Total literature 617 3 0.5 0–1.0
191 6 3.1 0.6–5.6 Present study
All data 808 9 1.1 0.4–1.8
.20 90 1 1.1 0–3.3 Cruger et al. (2003)
27 2 7.4 0–17.3 Bor et al. (2002)
430 13 3.0 1.4–4.6 Gekas et al. (2001)
10 1 10.0 0–28.6 van der Ven et al.
(1997)
Total literature 557 17 3.1 1.6–4.5
172 4 2.3 0.1–4.5 Present study
All data 729 21 2.9 1.7–4.1
aCategory not further speciﬁed.
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infertility, abnormal karyotypes were noted in 3.2% (95% CI 2.9–
3.6%) (Scholtes et al., 1998; van der Ven et al., 1998; Peschka et al.,
1999; Haidl et al., 2000; Gekas et al., 2001; Morel et al., 2004;
Clementini et al., 2005; Kayed et al., 2006; Riccaboni et al., 2008).
When considering only female partners of ICSI couples, in 4.1% (CI
3.4–4.9%) a chromosomal abnormality was found (Gekas et al.,
2001; Morel et al., 2004; Riccaboni et al., 2008). This is an unexpected
high prevalence, because in ICSI couples the male factor predominates
as the cause of infertility and female partners are usually considered as
representatives of the normal population. The risk of chromosomal
abnormalities might be increased in both male and female partners
of infertile couples when compared with newborns and sperm donors.
The guidelines of the ASRM, NICE and Dutch Society of Obstetrics
and Gynaecology on genetic testing in infertile males are based on
assumed high prevalences of chromosomal abnormalities in azoosper-
mic and severely oligozoospermic men. We conﬁrmed a signiﬁcantly
increased prevalence of chromosomal abnormalities in azoospermic
males (15.2%), justifying screening these men for chromosomal
abnormalities.
However, we did not ﬁnd a signiﬁcant difference between the
prevalence of abnormal karyotype in men with (severe) oligozoosper-
mia or normal sperm concentration but requiring ICSI. This prevalence
of 2.5% in non-azoospermic infertile men in our study questions
whether this whole group should be chromosomally screened. Karyo-
typing and genetic counselling are relatively costly and costs and
beneﬁts of testing should be weighed. Karyotyping may identify the
cause of male infertility, giving the couple some relief. However, this
will be the case in only a small minority of infertile couples. If the
main objective of karyotyping is to identify couples at risk of viable off-
spring with unbalanced structural chromosomal abnormalities, one
should note that the incidence of balanced rearrangements in oligo-
zoospermic men is 1% (O’Flynn O’Brien et al., 2010). For most
balanced rearrangements, the risk of a child with congenital anomalies
due to a chromosomal unbalance has been shown to be very small
(Franssen et al., 2006). In oligozoospermic men, the a priori risk of
a child with an unbalanced karyotype due to a paternal balanced
rearrangement is less than 1 in 10 000. This low risk can be considered
acceptable in the light of the commonly applied threshold of 1 in 250
used in prenatal Down syndrome screening. Therefore, we would
propose to limit screening for chromosomal abnormalities to infertile
couples with non-obstructive azoospermia.
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